Lovin George
Infectious Disease · Bismarck, NDNPI 1760036065
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,518 of the $2,826 with a category attached, or 89.1%. It is spread thinly across 29 manufacturers, the largest accounting for just 17.0% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,513, 4.0 times the $379 reported in 2022.
Across 120 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$479
- Astellas Pharma US Inc$290
- E.r. Squibb & Sons, L.L.C.$277
- AstraZeneca$216
- Regeneron Healthcare Solutions, Inc.$166
- Harmony Biosciences LLC$163
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,51889%
- Education$30711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 16 | $479 |
| Astellas Pharma US Inc | 4 | $290 |
| E.r. Squibb & Sons, L.L.C. | 16 | $277 |
| AstraZeneca | 3 | $216 |
| Regeneron Healthcare Solutions, Inc. | 9 | $166 |
| Harmony Biosciences LLC | 8 | $163 |
| Gilead | 4 | $154 |
| GSK | 8 | $121 |
| Johnson & Johnson | 6 | $91 |
| QOL Medical, LLC | 4 | $86 |
| Baxter Healthcare | 3 | $73 |
| Insmed, Inc. | 4 | $72 |
| Lilly USA, LLC | 4 | $70 |
| Merck | 3 | $68 |
| Melinta Therapeutics, LLC | 3 | $63 |
| Mallinckrodt Hospital Products Inc. | 3 | $62 |
| Bayer | 3 | $60 |
| United Therapeutics Corporation | 3 | $54 |
| Ardelyx, Inc. | 3 | $47 |
| Boehringer Ingelheim | 2 | $28 |
| Pfizer | 2 | $27 |
| Phathom Pharmaceuticals, Inc. | 2 | $25 |
| Ferring Pharmaceuticals Inc. | 1 | $23 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Vertex | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $18 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
| Aimmune Therapeutics, Inc. | 1 | $17 |
| Intercept Pharmaceuticals, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few infectious disease providers in North Dakotato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 50 | $194,263 |
| TivicayDolutegravir Sodium | 11 | $48,072 |
| Methenamine Hippurate | 23 | $1,361 |
| Fluconazole | 20 | $1,189 |
| Ethambutol Hcl | 19 | $793 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 25 | $403 |
| Azithromycin | 14 | $310 |
| Doxycycline Hyclate | 18 | $251 |
| Atorvastatin Calcium | 43 | $111 |
| Amlodipine Besylate | 12 | $7 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadBiktarvy | $154 | $194,26350 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few infectious disease providers in North Dakotaon file to place this against a meaningful peer group, so we don't.
Other infectious disease in Bismarck
- Noe MateoBismarck$6K
- Supha ArthursBismarck$5K
- Casmiar NwaigweMinot$39K
- Avish NagpalFargo$302
- Sara NausheenGrand Forks$223
- Sammantha KoubaFargo$209
- Timothy BischofFargo$112
- Augusto AlontoFargo$71
- Abiola FashanuFargo$63
- Suha Abu KhalafFargo$0
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.